TD Cowen analyst Chris Shibutani reiterated a Buy rating and {REMOVEPT} price target on Seres Therapeutics (NASDAQ: MCRB).The analyst commented ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE